Navigation Links
Heska Enters Distribution Agreement with MWI Veterinary Supply
Date:11/12/2012

LOVELAND, Colo., Nov. 12, 2012 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), a leading provider of veterinary diagnostic and specialty products, announced today a new distribution agreement with MWI Veterinary Supply.  MWI will inventory, market and promote the full line of Heska's veterinary products throughout the United States beginning January 2, 2013.  Certain products, such as the popular Vet/IV Infusion Pump, will be available through MWI immediately.

"We believe this partnership represents a significant opportunity," says Robert Grieve, Chairman and Chief Executive Officer of Heska Corporation.  "Improving the choices available for advanced diagnostic solutions will benefit both customers and the animal health industry as a whole, and improve business opportunities for both MWI and Heska."

"MWI is very pleased to offer our customers the additional solutions Heska's products provide.  We look forward to working with Heska as we continue our shared missions of serving veterinary professionals," said Jim Cleary, MWI President and Chief Executive Officer.

About Heska
Heska Corporation (NASDAQ: HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines.  The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at www.heska.com.

About MWI
MWI is a leading distributor of animal health products across the United States and the United Kingdom. MWI sells both companion animal and production animal products including pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, supplies, pet food, capital equipment and technologies used by veterinarians and producers.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. There are uncertainties regarding Heska's ability to successfully commercialize new products; competition, including new products competitors may introduce in the future; uncertainties related to Heska's market estimates; uncertainties regarding Heska's ability to gain market share in an economic manner; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.


'/>"/>
SOURCE Heska Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Heska Announces Third Quarter 2012 Earnings Conference Call Webcast
2. Heska Corporation Announces Amendment To Its Odd-Lot Tender Offer
3. Heska to Present at B. Riley Investor Conference
4. Heska Announces Quarterly Dividend of $0.10 Per Share
5. Presentations at Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes from Patients at More Than 40 Centers
6. Pharmalink Enters Manufacturing Agreement for Nefecon(R)
7. SAFC Enters South Korean BioPharma Market with CrystalGenomics Agreement
8. Surgical Equipment Market to 2018 - Increased Access to Ambulatory Surgical Centers to Drive Outpatient Surgery Volumes
9. Johnson & Johnson Announces Plans to Establish Innovation Centers
10. IBA Molecular Introduces Centers for Innovation
11. Jazz Pharmaceuticals Enters Definitive Agreement to Sell its Womens Health Business to Meda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/22/2017)... Peoria, IL (PRWEB) , ... May 22, 2017 ... ... HealthCare, is part of a larger group investing in InsightRX, an early stage ... a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund ...
(Date:5/21/2017)... FL (PRWEB) , ... May 20, 2017 , ... Pot. ... it, find it, review it, and share its attributes like never before. More than ... directory to connect cannabis enthusiasts to stores, strains, products – and for the first ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... longer than six months since you've seen a dentist, it's time for a ... and getting x-rays once per year. , Dental checkups are a relatively easy ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm ... Titled " Ten Good Reasons To Hire An Experienced Personal Injury Attorney, " the ... an accident or injury. As the article says. if someone is injured due ...
(Date:5/19/2017)... ... 19, 2017 , ... As a groundbreaking surgeon on the frontline of prostate ... screenings. Early detection of the disease, he says, can make a world of difference. ... , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and ...
Breaking Medicine News(10 mins):